Corporate Profile

PrintBio is a privately held, clinical- and commercial-stage biotechnology company and leader in regenerative medicine using novel 3D-bioprinting and material science technologies to deliver safe, functional and personalized products and living tissues and organs, engineered and produced on-demand for patients. The Company was founded and is led by an experienced team of biotechnology founders and executives.

For questions regarding investment opportunities, email: investors@printbio.com

Recent Updates

PrintBio Introduces DynaFlex™ Programmable Surgical Mesh (PSM) at American Hernia Society Meeting 2025

DynaFlex™ Incorporates MetaDirectional Flex™ Technology to Create the First-of-Its-Kind Programmable Mesh Our introduction of DynaFlex™ represents a new era in surgical repair. By giving surgeons programmable control over mesh mechanics,…

PrintBio Reorganizes and Expands Leadership Team with Key Commercial and Market Development Appointments

egalli | Press Releases | No Comments

• Launches Hernia Division to Focus on Abdominal Wall Repair Solutions • Strengthens Leadership to Drive Market Readiness for Surgical Innovation These appointments, encompassing a remarkable depth of talent and…

PrintBio Receives FDA Clearance for 3DMatrix DynaFlex™, Adding Uniflex™ Technology to 3DMatrix™, the First 3D-Printed Resorbable Surgical Mesh Approved Less than One Year Ago

egalli | News, Press Releases | No Comments

3DMatrix DynaFlex™ incorporates PrintBio’s proprietary Uniflex™ unidirectional flexible mesh technology PrintBio was founded by Rapha Capital Management, LLC and its investors through its SPV, Rapha Capital Investment XIV, LLC MIAMI,…

View All